Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CervoMed ( (CRVO) ) has shared an announcement.
On January 31, 2025, CervoMed provided an update on its development of neflamapimod for dementia with Lewy bodies, presented at the 8th International Lewy Body Dementia Conference. The RewinD-LB Phase 2b trial showed no significant differences between the neflamapimod and placebo groups during the 16-week double-blind phase, possibly due to the age of the drug batch. The company anticipates efficacy endpoint data from the open-label extension phase using newer capsules, which showed better plasma drug concentrations. These results will guide the next steps in neflamapimod’s development.
More about CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. It is currently developing neflamapimod, an orally administered small molecule designed to inhibit p38 mitogen-activated protein kinase alpha, which has potential in treating synaptic dysfunction in neurological disorders.
YTD Price Performance: 0.90%
Average Trading Volume: 444,925
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.57M
For detailed information about CRVO stock, go to TipRanks’ Stock Analysis page.
